Top in GI: Excess weight and colorectal cancer; herbal extracts in ulcerative colitis
Click Here to Manage Email Alerts
Individuals with a BMI of 30 kg/m² or more had an increased risk for colorectal cancer compared with individuals with normal weight, regardless of polygenic risk score, according to a study published in JAMA Network Open.
Researchers said the findings “add to the limited evidence” on associations between BMI, polygenetic risk score and colorectal cancer. It was the top story in gastroenterology last week.
Another top story was about the potential benefits of curcumin and QingDai in patients with active ulcerative colitis. Data showed that the herbal extracts induced clinical response and remission in this population.
Read these and more top stories in gastroenterology below:
Excess weight increased risk for colorectal cancer, independent of genetic risk
Excess weight, regardless of polygenic risk score, correlated with an increased risk for colorectal cancer, according to results from a population-based, case-control study. Read more.
Curcumin-QingDai induces remission in active UC, ‘paves the way’ for integration in care
The combination of herbal extracts curcumin and QingDai induced clinical response and remission in patients with active ulcerative colitis, according to data presented at the Crohn’s and Colitis Congress. Read more.
Smartwatches, wearable technology ‘may hold promise’ to identify, predict IBD flare
Wearable technology, including wrist-worn smartwatches that monitor heart rate variability, may help identify and predict flares of inflammatory bowel disease, data showed. Read more.
Advanced colorectal neoplasia prevalence remains low 10 years after negative colonoscopy
Researchers reported low prevalence for advanced colorectal neoplasms at screening colonoscopies conducted at least 10 years after a negative index colonoscopy, especially among women younger than 75 years. Read more.
Humira exclusivity expires in 2023: Will biosimilar boom benefit patients or industry?
In 2021, Humira — the blockbuster biologic that has for years been the highest grossing drug in the world — accomplished something that no drug had previously achieved when its global revenues topped $20 billion. Read more.